# Agent 1 Benchmark Report - 06_dose_evaluation

**Generated:** 2026-06-03 15:14:59
**Agent:** 1
**Category:** 06_dose_evaluation

## Executive Summary

| Metric | Value |
|--------|-------|
| Total Tests | 6 |
| Passed | 5 |
| Failed | 1 |
| Pass Rate | 83.3% |
| Avg Score | 0.808 |

### Failure Root Causes

| Root Cause | Count | % of Failures | Severity |
|------------|-------|---------------|----------|
| keyword_missing | 1 | 100.0% | P2 |

## Detailed Results

### ❌ Q1145

**Input:** Evaluate QA results: source strength 0.8% difference, dwell position max 0.8 mm deviation, point dose 1.7% difference. Are these within TG-59 tolerance?...

**Response:**
> **Yes, all three QA results are within TG-59 tolerances.**| Parameter | Measured | TG-59 Tolerance | Status ||-----------|----------|-----------------|--------|| Source strength | 0.8% difference | ±3% (acceptable), ±5% (action level) | ✅ Pass || Dwell position | 0.8 mm deviation | ±1 mm (tolerance), ±2 mm (action) | ✅ Pass || Point dose | 1.7% difference | ±3% (tolerance), ±5% (action) | ✅ Pass |**Interpretation:**- All values are well within **routine tolerance limits**- Source strength and point dose differences are negligible (<2%)- Dwell position deviation is sub-millimeter- No action required; continue routine QA schedule- Consider trending these values over time to detect systematic drift**TG-59 Action Levels:**- If any parameter exceeds action...

**Scores:**
- Total: 0.65
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1145](../screenshots/06_Q1145.png)

**Failure Analysis:**
- Root Cause: keyword_missing
- Description: No expected keywords found

---

### ✅ Q1615

**Input:** I need to understand the dose-rate dependence of brachytherapy sources. For Ir-192 HDR treatments, the dose rate at the prescription point is typically 5-12 Gy/hr. For Pd-103 LDR seeds, the initial dose rate is approximately 18 cGy/hr. How does the dose-rate effect (the 4 Rs of radiobiology) affect the biological effectiveness of these different brachytherapy approaches? Should I apply a biological effective dose (BED) correction when comparing HDR and LDR treatments?...

**Response:**
> ## Dose-Rate Dependence in Brachytherapy: Radiobiological Considerations### The 4 Rs and Dose-Rate Effects| Radiobiological Principle | HDR (5-12 Gy/hr) | LDR (~0.18 Gy/hr) | Clinical Implication ||---------------------------|------------------|-------------------|---------------------|| **Repair** | Minimal repair during exposure | Extensive sublethal damage repair | HDR requires lower total dose for equivalent cell kill || **Reoxygenation** | Limited within fraction | Complete between...

**Scores:**
- Total: 0.90
- Keyword: 0.71
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1615](../screenshots/06_Q1615.png)

---

### ✅ Q1626

**Input:** I am reviewing a brachytherapy plan for cervical cancer using a tandem and ovoid applicator. The plan shows point A dose of 6.0 Gy per fraction, with the following OAR doses: rectal point 4.2 Gy, bladder point 4.8 Gy. The prescription is for 5 fractions. I want to understand the TG-43 uncertainty budget for this plan. What are the main sources of uncertainty in the dose calculation? How should I combine the individual uncertainties? What is the total uncertainty at the 95% confidence level?...

**Response:**
> ## TG-43 Uncertainty Budget for Cervical Brachytherapy### Main Sources of Uncertainty**1. Source Strength Calibration (~3-5%)**- Well chamber calibration uncertainty- Reference standard traceability (NIST/ADCL)- Temperature/pressure corrections- Decay correction accuracy**2. Source Data Parameters (~2-3%)**- Dose-rate constant (Λ): 1-2%- Radial dose function g(r): 1-2%- Anisotropy function F(r,θ): 1-2%- Geometry function G(r,θ): <1%**3. Applicator/Patient Factors (~5-10%)**- Source position verification in applicator- Interfraction applicator movement- Tissue heterogeneity (not accounted in TG-43)- Patient anatomy changes...

**Scores:**
- Total: 0.82
- Keyword: 0.50
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1626](../screenshots/06_Q1626.png)

---

### ✅ Q1637

**Input:** I need to understand the effect of applicator heterogeneity on dose calculation in brachytherapy. For a vaginal cylinder applicator made of Delrin (plastic), how does the applicator material affect the dose distribution compared to water? What is the attenuation coefficient of Delrin for Ir-192 gamma rays? How should the applicator be modeled in the treatment planning system? What errors are introduced by assuming the applicator is water-equivalent?...

**Response:**
> ## Applicator Heterogeneity Effects in Brachytherapy: Delrin Vaginal Cylinders### Material Properties Comparison| Property | Delrin (Acetal) | Water | Clinical Impact ||----------|-----------------|-------|-----------------|| Density | 1.41 g/cm³ | 1.00 g/cm³ | Higher attenuation || Effective Z | ~7-8 | ~7.4 | Similar photon interactions || Linear attenuation (Ir-192) | ~0.10-0.12 cm⁻¹ | ~0.065 cm⁻¹ | 40-50% higher |### Dose Distribution Effects**Key findings...

**Scores:**
- Total: 0.82
- Keyword: 0.50
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1637](../screenshots/06_Q1637.png)

---

### ✅ Q1652

**Input:** I am performing a dose calculation for a prostate LDR implant using Pd-103 seeds. I need to understand the biological effective dose (BED) comparison between Pd-103 and I-125 implants. Given that Pd-103 has a half-life of 17 days versus 59.4 days for I-125, how does the dose-rate effect affect the biological effectiveness? What alpha/beta ratio should I use for prostate cancer? How do the BED values compare for equivalent physical dose prescriptions?...

**Response:**
> ## BED Comparison: Pd-103 vs I-125 LDR Implants### Half-Life and Dose Rate Implications| Parameter | I-125 | Pd-103 ||-----------|-------|--------|| Half-life | 59.4 days | 17.0 days || Initial dose rate | ~8-10 cGy/hr | ~18-20 cGy/hr || Mean lifetime | 85.7 days | 24.5 days || Energy | 27-35 keV (avg 28 keV) | 20-23 keV (avg 21 keV) |### BED Formula for LDR Brachytherapy$$BED = D \times \frac{(\alpha/\beta + D_{initial}/g)}{\alpha/\beta}$$For continuous low dose rate (CLDR) with...

**Scores:**
- Total: 0.82
- Keyword: 0.50
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1652](../screenshots/06_Q1652.png)

---

### ✅ Q1657

**Input:** I need to understand the TG-218 report on tolerance formalism and methodology for radiation oncology. How do the TG-218 tolerance categories apply to brachytherapy? What are the specific tolerance values for: (1) source strength calibration, (2) source position accuracy, (3) dose calculation accuracy, and (4) dose delivery accuracy? How should I implement TG-218 tolerance checking in my brachytherapy QA program?...

**Response:**
> ## TG-218 Tolerance Framework for Brachytherapy QA### OverviewTG-218 (2018) establishes a risk-informed tolerance formalism based on the **margin-of-error (MoE)** approach rather than fixed percentage tolerances. For brachytherapy, this translates to:---### Key Tolerance Values for Brachytherapy| Parameter | TG-218 Tolerance | Action Level ||-----------|------------------|--------------|| **Source strength calibration** | ±5% from certificate | ±3% for action || **Source position (dwell)** | ±2 mm | ±1 mm for action || **Dose calculation** | ±5% | ±3% for action || **D...

**Scores:**
- Total: 0.82
- Keyword: 0.50
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1657](../screenshots/06_Q1657.png)

---

